Lung Microbiota Analysis in Critically Ill Patients Admitted to the Intensive Care Unit.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-15

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our study aims to evaluate the relationship between the heterogeneity of pulmonary microbiota and clinical and outcome variables among critically ill patients admitted to the intensive care unit (ICU). In patients undergoing invasive mechanical ventilation, an aliquot of bronchoalveolar lavage (BAL) fluid will be used in the microbiology laboratory for the analysis of respiratory microbiota through next-generation sequencing technologies and validate computational techniques.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Alterations of the Microbiome During Critical Illness With Short and Long Term Clinical Outcomes

NCT04552834

Critical Illness Microbiome

ACTIVE_NOT_RECRUITING

Study on ICU Patients With Nosocomial Lower Respiratory Tract Infections

NCT03183921

Pneumonia

UNKNOWN

Infection Surveillance in Intensive Care Patients

NCT00197847

Infection Pneumonia Sepsis +1 more

UNKNOWN

Pneumonia Due to Stenotrophomonas Maltophilia in ICUs

NCT03506191

Pneumonia, Ventilator-Associated Stenotrophomonas Infection Critical Illness +1 more

UNKNOWN

Bronchoalveolar Lavages for Cytologic Assessment in Intensive Care Unit Patients

NCT03098888

Lung Diseases Intensive Care

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Traditionally, microbiological investigations and clinical trials have contributed to the definition of lower airways as a physiologically sterile district, whose microbiological balance is altered when a respiratory infectious process occur. Actually, the introduction of molecular study methods aiming at the identification of pathogens through genomic sequencing questioned the pardigm of "one bug-one disease", according to which we usually tend to consider a bronchial or pulmonary infectious event as due to the pathogenic role of a single exogenous microorganism. In such a contest, there are truly few data dealing with the characterization of respiratory microbiota in human BAL as well as with the major determinants of this phenomenon and the possible impact on clinical and microbiological outcomes. Our study, although it's a pilot one, aims to evaluate these aspects in a larger cohort of critically ill patients, observing the relationship between the heterogeneity of pulmonary microbiota and clinical and outcome variables. In patients undergoing invasive mechanical ventilation, an aliquot of BAL fluid will be used in the microbiology laboratory for the analysis of respiratory microbiota through next-generation sequencing technologies and validate computational techniques. For each enrolled patient, we will register demographic, clinical and laboratory variables. The benefits deriving from this study lay in the possibility of improving the understanding of characteristics of critical patient's pulmonary microbioma and its clinical impact. Such an information meets the increasingly topical need to customize medical interventions, especially in the context of critically ill patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* execution of bronchoalveolar lavage sampling, either for clinical indications or in the context of surveillance programs
* acquisition of an informed consent

Exclusion Criteria

* presence of significant coagulation abnormalities and/or severe respiratory failure
* clearly bloody BAL sample
* small quantity of BAL sample (\<5 ml)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No